Hepalink to acquire Cytovance

Wednesday, August 26, 2015

Hepalink USA, a China-based global supplier of heparin sodium API, has entered into a definitive agreement to acquire Cytovance Biologics, a biopharmaceutical contract development manufacturing (CDMO) company, for $205.68 million in cash plus certain contingent payments.

[Read More]

China to reform drug approval system

Thursday, August 20, 2015

China has decided to reform its appraisal and approval system for drugs and medical instruments with the aim of improving drug safety and quality and encouraging innovation.

[Read More]

First made-in-Singapore cancer drug enters clinical testing

Thursday, July 23, 2015

A made-in-Singapore cancer drug has advanced into clinical trials, charting a milestone in Singapore’s biomedical sciences initiative that will go towards improving the lives of cancer patients in Singapore, and worldwide. The Agency for Science, Technology and Research (A*STAR) and Duke-National University of Singapore Graduate Medical School (Duke-NUS) have announced the start of a phase I clinical trial of novel cancer drug candidate, ETC-159.

[Read More]

Sun Pharma closes merger deal with Ranbaxy

Thursday, March 26, 2015

Sun Pharmaceutical Industries has begun the integration of Ranbaxy‘s business following the successful closure of its merger. The integration, planned by Sun Pharma since the announced merger in April 2014, will focus on supporting strong growth. According to Sun Pharma, the merger has fortified its position as the world’s fifth largest specialty generic pharmaceutical company and the top ranking Indian pharma company.

[Read More]

Eli Lilly inks deals with Innovent Biologics, Hanmi Pharmaceutical

Friday, March 20, 2015

Eli Lilly and Innovent Biologics, a biopharmaceutical company in China, have inked a biotech drug development collaboration to collaborate to support the development and potential commercialization of at least three cancer treatments over the next decade. The agreement creates possible new treatment options for cancer patients, while strengthening the presence of both companies in the Chinese oncology market.

[Read More]